BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1279261)

  • 1. [Significance of prostatic specific antigen in the mass screening for prostate cancer].
    Imai K; Suzuki T; Kuribara J; Ito K; Ootake N; Hatori M; Yamanaka H; Tomaru Y; Jinbo S; Kiren H
    Nihon Hinyokika Gakkai Zasshi; 1992 Sep; 83(9):1484-9. PubMed ID: 1279261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Measurement of serum PSA by DELFIA PSA kit and its application for mass screening. The Gunma Urological Oncology Study Group].
    Imai K; Watanabe K; Higashi H; Shinya H; Okamura K; Matsuo Y; Yazima H; Takezawa Y; Yamanaka H
    Hinyokika Kiyo; 1993 Sep; 39(9):807-12. PubMed ID: 7692709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen in mass screening for carcinoma of the prostate.
    Shimizu TS; Uchida T; Satoh J; Imai K; Yamanaka H
    Int J Urol; 1995 Sep; 2(4):257-60. PubMed ID: 8564745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostatic specific antigen (PA) in mass screening for prostate cancer].
    Ito K; Ohtake N; Hatori M; Mashimo T; Jimbo S; Tomaru Y; Makino T; Yajima H; Imai K; Yamanaka H
    Hinyokika Kiyo; 1992 Nov; 38(11):1225-9. PubMed ID: 1283053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M; Okada K
    Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
    Dell'Atti L
    J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital.
    Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO
    West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative contribution of digital rectal examination and transrectal ultrasonography in interpreting serum prostate-specific antigen values for screening prostate cancer in Arab men.
    Sheikh M; Sinan T; Kehinde EO; Hussein AY; Anim JT; Al-Hunayan AA
    Ann Saudi Med; 2007; 27(2):73-8. PubMed ID: 17356323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study.
    Bretton PR
    South Med J; 1994 Jul; 87(7):720-3. PubMed ID: 7517580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less.
    Yamamoto T; Ito K; Ohi M; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Urology; 2001 Dec; 58(6):994-8. PubMed ID: 11744475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of prostate specific antigen for early stage prostate cancer detection.
    Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J; Saitoh M; Watanabe H; Ohe H
    Jpn J Clin Oncol; 1994 Jun; 24(3):160-5. PubMed ID: 7516445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital rectal examination is barrier to population-based prostate cancer screening.
    Nagler HM; Gerber EW; Homel P; Wagner JR; Norton J; Lebovitch S; Phillips JL
    Urology; 2005 Jun; 65(6):1137-40. PubMed ID: 15922431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.